Looking for dividend shares to buy? Listed below are two ASX dividend shares that analysts rate as buys.

Here’s why they are bullish on these dividend shares:

Adairs Ltd (ASX: ADH)

The first ASX dividend share to look at is this furniture and homewares retailer.

Its shares have been hammered this year and have lost over 40% of their value. While this is disappointing, Goldman Sachs believes it has created a buying opportunity and has put a buy rating and $2.65 price target on the company’s shares.

Its analysts believe the market is being too negative on Adairs’ outlook. It notes that “the market is pricing in EBIT that is 11-21% below the guidance range, and 12% below GSe.” It also highlights that it views “the core Adairs business as resilient in the current environment and do not believe the c.40% discount to discretionary retail peers is justified.”

Goldman is forecasting fully franked dividends per share of 17 cents in FY 2023 and 20 cents in FY 2024. Based on the latest Adairs share price of $2.22, this will mean yields of 7.7% and 9%, respectively.

Rural Funds Group (ASX: RFF)

Another ASX dividend share to consider is this Australian agricultural property company.

Its shares have also taken a tumble in 2022, which has caught the eye of analysts at Bell Potter.

The broker recently upgraded Rural Funds’ shares to a buy rating with a $2.75 price target on the belief that this share price weakness has created a buying opportunity. Bell Potter notes that “the current discount to adjusted NAV reflects what historically would be considered an attractive entry point.”

In addition, the broker is expecting Rural Funds’ dividend to continue growing in the coming years.

It is forecasting an 11.7 cents per share dividend in FY 2023 and then a 12.7 cents per share dividend in FY 2024. Based on the current Rural Funds share price of $2.57, this represents yields of 4.55% and 5%, respectively.

The post These growing ASX dividend shares are buy: analysts appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Ballin’ on a budget: The best ASX shares to buy for under $5
• 3 key things I look for when buying ASX dividend shares
• How I’d invest in ASX dividend shares now to make a $50k passive income in retirement
• Amidst the ongoing tech stock wreck, value shares are everywhere. There’s just one catch…
• Could ASX 200 retail shares be ‘too cheap’ to ignore right now? Here’s Scott Phillips’ take

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ADAIRS FPO. The Motley Fool Australia has positions in and has recommended ADAIRS FPO and RURALFUNDS STAPLED. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/9PDyjAG

The Imugene Limited (ASX: IMU) share price has had a tough run lately.

Imugene shares have dropped nearly 12% since market close on 15 November. The company’s share price was flat today and closed the day trading at 19 cents.

Let’s take a look at what is happening at Imugene.

What’s going on?

Imugene is a biotechnology company working on immunotherapies to treat cancer.

The Imugene share price descended nearly 10% last Wednesday,1 6 November. The S&P/ASX 200 Health Care Index (ASX: XHJ) also lost 1% on this day.

The dramatic fall on Wednesday followed the company’s share price soaring 5% on Tuesday, 15 November.

Imugene provided an investor presentation to the market on this day. The company highlighted it had $163.8 million in cash as of 30 September. The company has five unique assets, three platform technologies, 2 supply agreements, three scientific collaborations and 10 clinical studies.

On 17 November, Imugene held its AGM. The company’s share price was flat on this day. All resolutions at the meeting were carried but the company noted more than 25% voted against the 2022 remuneration report.

Highlights in 2022 included positive overall survival results in phase two of the HER-Vaxx trial, a clinical trial agreement with Roche to investigate the PD-1-Vaxx in combination with Tecentriq and cohort three cleared in the phase one study of CHECKvacc for treatment of patients with triple negative breast cancer. In the Vaxinia trial, the first patients were dosed and cleared in IV cohort 1 and IT cohort 2.

On 11 November, Imugene advised it has escalated the dose in the phase one clinical trial of Vaxinia. This treatment has been shown to shrink cancer tumours in animal models.

Imugene share price snapshot

The Imugene share price has tumbled 65% in the past year, while it has fallen 57% year to date.

For perspective, the ASX 200 has fallen nearly 3% in the last year.

Imugene has a market capitalisation of $1.14 billion based on the current share price.

The post Why has the Imugene share price tumbled 12% in under a week? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/IZPRDXB

The Mesoblast limited (ASX: MSB) share price took flight on Monday, soaring 9% to an intraday high of $1.02 before losing some ground in afternoon trading.

Shares in the ASX biotech company closed at 99 cents apiece today, up 6.45% from 93 cents at the market open.

The overall healthcare sector kicked off the week well, too, with the S&P/ASX 200 Health Care Index (ASX: XHJ) gaining 0.48%.

On a broader scale, the S&P/ASX 200 Index (ASX: XJO) petered out after a healthy start this morning to finish an unremarkable 0.17% lower.

Let’s take a look at what may have influenced the Mesoblast share price on Monday.

What happened?

There’s no news to report from Mesoblast today, and in fact, an absence of noteworthy announcements from the company for some time.

Our Fool writers last wrote about Mesoblast at the start of this month when we covered the company’s quarterly activities and cashflow report.

However, there are a couple of reasons that could help explain why Mesoblast’s shares have jumped higher. For one, the report noted that the company expected to receive FDA clearance to trial rexlemestrocel-L as a treatment for chronic back pain near the end of this year.

Rexlemestrocel-L and Remestemcel-L are the company’s mesenchymal precursor cell (MPC) products that Mesoblast is developing to treat various diseases.

Another possible share price driver today is that its annual general meeting (AGM) is approaching fast. Mesoblast will hold its AGM on Wednesday this week in Melbourne.

Some measures shareholders will vote on include the election and re-election of company directors and ratifying the issue of fully paid ordinary shares to major shareholders.

Mesoblast share price snapshot

The Mesoblast share price is down 29.29% year to date and a hefty 42% over the past 12 months. In comparison, the S&P/ASX 200 Index is down a respective 5.9% and 2.9% across the same time periods.

The company’s market capitalisation is around $729.7 million.

The post Why did the Mesoblast share price soar 9% today? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Here are the 3 most heavily traded ASX 200 shares on Monday
• Why is the Rio Tinto share price trailing the ASX 200 on Monday?
• Why is the Lake Resources share price smashing the ASX 200 on Monday?
• 3 ASX 200 shares that hiked their dividends by more than 100% this year

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/yqdQwjP

The dividends coming out of AGL Energy Limited (ASX: AGL) shares these days might not be of the same magnitude as days of yore. AGL is an ASX share that has been famously struggling in recent years.

Case in point, the AGL share price was over $23 five years ago.

Today, it is under $8, having lost more than 67% of its value since November 2017.

But despite its recent woes, AGL is still an ASX dividend share. So let’s check out what kind of dividend income an AGL investor would have enjoyed over 2022.  

Here’s how much dividend income AGL shares have paid out this year

So let’s say an investor put $20,000 into AGL shares at the start of the year. AGL finished 2021 at a share price of $6.14, so we’ll use that as our anchor point.

$20,000 would have bought our investor 3,257 AGL shares with the $20,000 of capital at the start of the year, with some change left over.

So AGL has paid out two dividends over 2022. The first was the interim dividend of 16 cents per share that investors received on 30 March. The second was the final dividend of 10 cents per share that was paid out on 27 September. Both payments were unfranked.

Those payments pale in comparison to the kinds of dividends AGL used to pay out. Back in 2017, investors enjoyed an interim dividend worth 41 cents per share, and a final dividend worth 50 cents per share. Those dividends came partially franked at 80% too.

But alas, that was then, not now.

So with our 3,257 AGL shares, 2022’s interim dividend of 16 cents per share would have invited a payment of $521.12. The final dividend of 10 cents per share would have entitled our investor to another payment of $325.70.

Together, that is a total of $846.82 in dividend income from our 3,257 AGL shares. This represents a yield on the $20,000 cost of 4.23%. It would be worth a yield of 3.3% on the AGL share price of $7.88, which is where the company closed at this afternoon.   

The post How much dividend income would $20,000 worth of AGL shares have netted you in 2022? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• 5 of the craziest things making news on the ASX this week
• AGL share price slips amid Cannon-Brookes’ board victory
• Why did the AGL share price lag the ASX 200 on Monday?
• Could the flurry of recent takeover bids mean ASX 200 shares are going cheap right now?

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Si0sXd3